Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
09 mai 2024 16h01 HE
|
Nkarta, Inc.
Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024Cash balance of $450.0 million on March 31, 2024, including cash, cash...
Nkarta to Participate in Upcoming Investor Conferences
03 avr. 2024 16h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its...
Nkarta Announces Pricing of $240 Million Underwritten Offering
25 mars 2024 06h30 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the...
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
21 mars 2024 16h01 HE
|
Nkarta, Inc.
First patient dosing on track for first half of 2024 in clinical trial of NKX019 in lupus nephritis using disease-tailored lymphodepletionAdditional B-cell mediated autoimmune diseases under...
Nkarta to Participate in Upcoming Investor Conferences
28 févr. 2024 08h01 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its...
Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition
09 déc. 2023 20h31 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today...
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
09 nov. 2023 16h02 HE
|
Nkarta, Inc.
FDA clearance of IND for NKX019 in lupus nephritis expands pipeline into autoimmune diseaseNKX019, a first-in-class engineered NK cell therapy, has disease-modifying potential in autoimmune disease...
Nkarta to Participate at Upcoming Investor Conferences
07 nov. 2023 08h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its...
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
17 oct. 2023 07h01 HE
|
Nkarta, Inc.
New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell...
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
16 oct. 2023 16h01 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that...